BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 23054114)

  • 1. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
    Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
    Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
    Zang RY; Harter P; Chi DS; Sehouli J; Jiang R; Tropé CG; Ayhan A; Cormio G; Xing Y; Wollschlaeger KM; Braicu EI; Rabbitt CA; Oksefjell H; Tian WJ; Fotopoulou C; Pfisterer J; du Bois A; Berek JS
    Br J Cancer; 2011 Sep; 105(7):890-6. PubMed ID: 21878937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
    Chung HH; Kwon HW; Kang KW; Park NH; Song YS; Chung JK; Kang SB; Kim JW
    Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
    Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
    Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
    Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
    Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
    Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
    World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.